Thyroid and Esophageal Cancer Therapeutic Pipeline Market (Drugs & Companies) Review H2 2014
Dallas, Tx (PRWEB) December 07, 2014 -- The report "Thyroid Cancer Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thyroid Cancer and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/thyroid-cancer-pipeline-review-h2-2014-market-report.html .
Thyroid cancer cancer is a cancer via follicular or parafollicular hypothyroid cells. Thyroid cancer is a dangerous growth that starts in the cells of a hypothyroid problem. Dangerous means that it can spread, or spread, to other parts of the body. Companies discussed in this Thyroid Cancer Pipeline Review H2 2014 report include AstraZeneca PLC, Azaya Therapeutics Incorporated, Bio-Path Holdings, Inc., Biovista Inc., centrose llc, Ecrins Therapeutics SAS, Eisai Co., Ltd., GlaxoSmithKline plc, Novartis AG, Translational Therapeutics, Inc., Trophogen, Inc. & Vascular Biogenics Ltd.
Drugs profile discussed in this Thyroid Cancer Pipeline Review H2 2014 report include BP-100-1.02, BVA-501, BVA-701, docetaxel liposomal, EDC-1, ETD-5, everolimus, Gene Therapy to Activate p53 for Oncology, GSK-2256098, lenvatinib, MVX-ONCO-1, panobinostat, pazopanib hydrochloride, Recombinant Protein to Agonize VEGF for Thyroid and Multiple Other Cancers, selumetinib sulfate, Small Molecules to Antagonize ALK for Oncology, Small Molecules to Inhibit PAK for Thyroid Cancer, TR-1401, TRX-201 and VB-111. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=248275 .
The report " Esophageal Cancer Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/esophageal-cancer-pipeline-review-h2-2014-market-report.html .
Esophageal melanoma is melanoma coming up from the foodpipe known as the wind pipe that operates between the neck and the abdomen. Companies discussed in this Esophageal Cancer Pipeline Review H2 2014 report include Advantagene, Inc., Advaxis, Inc., Amgen Inc., ArQule, Inc., Aslan Pharmaceuticals Pte. Ltd., AstraZeneca PLC, AVEO Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Cerulean Pharma, Inc., Daiichi Sankyo Company, Limited, Genmab A/S, GlaxoSmithKline plc, Glycotope GmbH, Hutchison MediPharma Limited, ImmunoFrontier, Inc., ImmunoGen, Inc., Immunomedics, Inc., Karyopharm Therapeutics, Inc., Mebiopharm Co., Ltd., Meiji Seika Pharma Co., Ltd., Merrimack Pharmaceuticals, Inc., Novartis AG, Omeros Corporation, Omnitura Therapeutics Inc., Oncolys BioPharma Inc., Ono Pharmaceutical Co., Ltd., Patrys Limited, Pfizer Inc., Precision Biologics, Inc., Recepta Biopharma S.A., Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Supratek Pharma Inc., Synta Pharmaceuticals Corp., Takara Bio Inc., Transgene Biotek Limited.
Drugs profile discussed in this Esophageal Cancer Pipeline Review H2 2014 report include 1-BB1, ADXS-HER2, afatinib, alpelisib, AMG-337, binimetinib, BMS-833923, Cell Therapy 1 for Oncology, Cell Therapy to Target NY-ESO-1 for Oncology, cetuximab biobetter, CRLX-101, dacomitinib, DKN-01, doxorubicin, ficlatuzumab, ganetespib, gefitinib, paclitaxel albumin bound, Oncolytic Virus for Oncology etc. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=248268 .
Reasons to buy
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore more reports on cancer therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .
About Us:
RnRMarketReserach.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Ritesh Tiwari, RnR Market Research, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article